> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GW Pharma sNDA for Cannabidiol Product
- URL: https://www.fdaweb.com/gw-pharma-snda-for-cannabidiol-product/
- Published: 2020-02-03T12:00:00.000Z
- Updated: 2026-09-14T16:01:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145997

GW Pharmaceuticals has submitted a supplemental NDA for Epidiolex (cannabidiol) oral solution for an expanded use to include seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition. Epidiolex is currently approved in the U.S. to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. The submission is based on Phase 3 data showing that Epidiolex reduced TSC-associated seizures, which include both focal and generalized seizures types, the company says. TSC is a condition that causes mostly benign tumors to grow in vital organs including the brain, heart, eyes, kidneys and lungs, and is a leading cause of genetic epilepsy.